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Background: The overall treatment time of stereotactic body radiotherapy (SBRT) for non-small-cell lung cancer is
usually 3 to over 10 days. If it is longer than 7 days, tumor volume expansion during SBRT may jeopardize the target
dose coverage. In this study, volume change of stage I NSCLC during SBRT was investigated.
Methods: Fifty patients undergoing 4-fraction SBRT with a total dose of 48 Gy (n = 36) or 52 Gy (n = 14) were
analyzed. CT was taken for registration at the first and third SBRT sessions with an interval of 7 days in all patients.
Patient age was 29–87 years (median, 77), and 39 were men. Histology was adenocarcinoma in 28, squamous cell
carcinoma in 17, and others in 5. According to the UICC 7th classification, T-stage was T1a in 9 patients, T1b in 27,
and T2a in 14. Tumor volumes on the first and 8th days were determined on CT images taken during the exhalation
phase, by importing the data into the Dr. View/LINAX image analysis system. After determining the optimal threshold
for distinguishing tumor from pulmonary parenchyma, the region above −250 HU was automatically extracted
and the tumor volumes were calculated.
Results: The median tumor volume was 7.3 ml (range, 0.5-35.7) on day 1 and 7.5 ml (range, 0.5-35.7) on day 8.
Volume increase of over 10% was observed in 16 cases (32%); increases by >10 to ≤20%, >20 to ≤30%, and >30% were
observed in 9, 5, and 2 cases, respectively. The increase in the estimated tumor diameter was over 2 mm in 3 cases
and 1–2 mm in 6. A decrease of 10% or more was seen in 3 cases. Among the 16 tumors showing a volume
increase of over 10%, T-stage was T1a in 2 patients, T1b in 9, and T2a in 5. Histology was adenocarcinoma in 10
patients, squamous cell carcinoma in 5, and others in 1.
Conclusions: Volume expansion >10% was observed in 32% of the tumors during the first week of SBRT, possibly
due to edema or sustained tumor progression. When planning SBRT, this phenomenon should be
taken into account.Background
Stereotactic body radiotherapy (SBRT) has become an
important treatment option for stage I non-small-cell
lung cancer (NSCLC) in recent years. Many reports have
shown that SBRT is safe and effective for stage I NSCLC,
since SBRT produces superior dose distribution within
the target, while reducing the irradiated normal tissue
volume compared with conventional radiotherapy [1-4].
However, the optimal dose fractionation schedule has
not been established yet; a variety of schedules are being
used at respective institutions, including 45–60 Gy in 3* Correspondence: koto5102000@yahoo.co.jp
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stated.or 4 fractions over 1–2 weeks and 55–65 Gy in 8 or
more fractions over 2–3 weeks [5-9]. In Japan, 48 Gy
delivered in 4 daily fractions has been the most fre-
quently used schedule, as was used in the Japan Clinical
Oncology Group (JCOG) study 0403 [10].
On the other hand, our group proposed a treatment
protocol based on radiobiological background, employing
different doses depending on tumor diameter and inter-
fraction intervals of 3 days or longer [11-13]. The rationale
for the strategy of twice weekly treatment was that the
reoxygenation phenomenon of tumors could be better
utilized by posing a longer interval between respective
fractions [14,15]. With this strategy, however, the overall
treatment time becomes longer, so changes in tumor size
during the SBRT course may become a problem, sinceal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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start of treatment. In the present study, therefore, we
evaluated tumor volume changes during SBRT for stage I
NSCLC using a computer image analysis tool.
Methods
Study design and subjects
The study subjects were patients enrolled in a prospective
SBRT study approved by the institutional review board of
Nagoya City University Hospital (NCU-0401). Details and
early clinical results of the study were reported previously
[11-13]. Eligibility criteria of the study were as follows: (1)
histologically confirmed primary NSCLC; (2) T1N0M0 or
T2N0M0 disease according to the International Union
Against Cancer (UICC) 1997 system by CT of the chest
and upper abdomen, brain magnetic resonance imaging,
and bone scintigraphy or 18-fluoro-deoxyglucose positron
emission tomography; (3) greatest tumor dimension ≤ 5 cm;
(4) World Health Organization performance status (PS) ≤ 2
or PS 3 when the cause was not a pulmonary disease; (5)
no prior chest radiotherapy for the NSCLC to be treated
by SBRT; (6) no active concurrent malignancy; and (7)
written informed consent.
SBRT was delivered in 4 fractions, twice a week. Accord-
ing to the protocol, all patients treated at Nagoya City
University Hospital underwent CT for registration at
the first and third SBRT sessions. Fifty patients treated
between July 2004 and August 2007 in whom the interval
between the 1st and 3rd fractions was just 7 days were
analyzed in this study (Table 1). Thirty-nine patients
were male and 11 were female. Patient age ranged from
29 to 87 years (median, 77 years). Thirty-eight patients were
medically inoperable and 12 refused surgery. Histology
was adenocarcinoma in 28, squamous cell carcinoma in
17, and others in 5. Maximum tumor diameter ranged
from 15 to 47 mm (median, 28 mm). According to the
UICC 7th staging system, 9 patients had a T1a tumor, 27
had a T1b tumor, and 14 had a T2a tumor.
SBRT methods
Our SBRT method has been described in detail previously
[11-13]. Briefly, SBRT was performed using 3 coplanarTable 1 Patient characteristics
All cases (n = 50) Enlarge
Sex (male/female) 39/11 14/2
Age (years) 77 (29–87) 76 (68–
Median (range)
T-stage T1a/T1b/T2a 8/28/14 2/9/5
Tumor diameter (mm) 28 (14–47) 27 (18–
Median (range)
Histology AD/SCC/others 29/16/5 10/5/1
AD = adenocarcinoma, SCC = squamous cell carcinoma, others = non-small-cell carciand 4 non-coplanar static beams of 6-MV X rays from
a linear accelerator (CLINAC 23EX, Varian Medical
Systems, Palo Alto, California, USA). The prescribed
total dose at isocenter was 48 Gy for T1a and T1b tumors
and 52 Gy for T2a tumors, all given in 4 fractions. The
total dose was 48 Gy in 36 patients and 52 Gy in 14. The
Body Fix system (Medical Intelligence, Schwabmenchen,
Germany) was used for patient immobilization.Evaluation of tumor volume
CT was taken just before the first and third treatments
(days 1 and 8) under free-breathing conditions and breath
holding during the exhalation and inhalation phases. For
this study, CT images taken under breath holding during
the exhalation phase were used because CT images at this
phase were considered to be of the highest reproduci-
bility in serial examinations. CT images were acquired
using a multidetector-row scanner (MX-8000, Philips,
Best, Netherlands) as described previously [16]. The scan-
ning parameters were as follows: detector configuration,
2.5 × 4; slice thickness, 3.2 mm; increment, 2.5 mm;
pitch, 0.875; rotation time, 0.75 sec; 120 kV; and 150
mAs/slice.
All CT datasets were imported to the image analysis
system, Dr. View/LINAX (AJS Inc., Tokyo, Japan), and
analyzed with the window level setting appropriate for
the lung (window width, 1,400 Hounsfield units, HU;
window level, -400 HU). We carefully measured the
CT number (HU) of lung tumors and pulmonary par-
enchyma, and determined the level of −250 HU as the
optimal threshold that distinguishes between them.
The region above −250 HU was automatically ex-
tracted and we then manually excluded the structures
outside the tumors such as vessels and chest walls
(Figure 1). Thereafter, tumor volumes were calculated
using this system. Preliminarily, this procedure was
repeated three times for 5 tumors selected randomly,
and we confirmed that the tumor volumes were calcu-
lated within 3% variation. Tumor diameter was esti-
mated assuming a spherical shape from the equation:








Figure 1 Method to evaluate tumor volume using an image analyzing system, Dr. View/LINAX. (A) First, the CT images were displayed at
an optimal window level of −400 HU with a width of 1,400 HU. (B) The region above −250 HU was automatically extracted (gray areas). (C) The
gray-painted structures outside the tumors such as vessels and chest walls (arrows) were manually excluded, and the tumor volume of the
gray-painted regions was calculated.
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Differences between pairs of groups were examined by
t-test or Fisher’s exact test.
Results
The median tumor volume was 7.3 ml (range, 0.5-35.7)
on day 1 and 7.5 ml (range, 0.5-35.7) on day 8. Figure 2
shows the tumor volumes on days 1 and 8 in all 50 patients.
Changes in the tumor volume and the tumor diameter
estimated from the tumor volume are shown in Table 2.
The relationship between tumor volume on day 1 and
volume change is shown in Figure 3. A volume increase
of over 10% was observed in 16 cases (32%); increases
by >10 to ≤20%, >20 to ≤30%, and >30% were observed
in 9, 5, and 2 cases, respectively. An increase of the es-
timated tumor diameter over 1 mm was observed in 9
patients (18%), among whom 3 (6%) showed an increase
over 2 mm.
A volume decrease of 10% or more was observed in 3
patients (6%); two had an adenocarcinoma and one had a
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Figure 2 Tumor volumes on day 1 and day 8 in all 50 patients.decrease of 38% was a squamous cell carcinoma. Three
patients (6%) showed a decrease of 1 mm or more in the
estimated diameter.
Characteristics of 16 patients showing more than 10%
increase and 34 patients showing no increase are listed
in Table 1. There were no differences in T-stage, tumor
size, and distribution of histology between the two groups.
For 29 adenocarcinomas, the volume change was 7.5 ± 14%
(mean ± SD), while it was 0.8 ± 16% for 16 squamous cell
carcinomas (P = 0.14).
Discussion
In this study, we evaluated changes of tumor volume
measured using an image-analyzing system, instead of
the gross tumor volume (GTV) delineated manually in
actual radiotherapy planning. The tumor volume measured
on the basis of the CT number is smaller than the GTV in
actual planning, since the system recognized only the solid
parts on one phase CT image (expiratory phase) and did
not contain spiculae and internal margins. As a result, we
could objectively evaluate slight changes in tumor volume
during the treatment. With this method, two issues exist
regarding possible mismeasurement of the tumor volume.
The first one is regarding delineation of the structures
close to the tumor. Especially when the tumor is adjacent
to the chest wall, it is sometimes difficult to separate theTable 2 Changes in tumor volume and diameter
Change in volume (%) n (%) Change in diameter (mm) n (%)
≤ − 30 1 (2) ≤ − 3 1 (2)
> − 30, ≤ − 20 1 (2) > − 3, ≤ − 2 1 (2)
> − 20, ≤ − 10 1 (2) > − 2, ≤ − 1 1 (2)
> − 10, ≤0 13 (26) > − 1, ≤0 13 (26)
>0, ≤10 17 (34) >0, ≤1 25 (50)
>10, ≤20 9 (18) >1, ≤2 6 (12)
>20, ≤30 5 (10) >2, ≤3 2 (4)
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Figure 3 Relationship between tumor volume changes and
tumor volume on day 1 in all 50 patients.
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the anatomical location of the chest wall. We measured
the same tumor three times and confirmed that the errors
for the tumor volume estimation were within 3% variation.
The second point is setting of the threshold to distinguish
the lung parenchyma and tumor. Adequate CT numbers
could differ among cases; the HU of regions like ground-
glass opacity may be smaller than that for solid lesions.
Nevertheless, we used −250 HU as the threshold in all
cases because we apprehended that changing the thresh-
old in respective cases would decrease the objectivity. We
considered that using the same threshold would not be a
major problem for the comparison of tumor volumes on
the first and eighth days.
Decrease in tumor volume of 10% or more was observed
in 3 (6%) patients. Previous studies indicated that squamous
cell carcinomas regress faster than adenocarcinomas after
Gamma Knife treatment or lung SBRT [17,18], but in the
present study, 2 of the 3 tumors were adenocarcinomas
while one was a squamous cell carcinoma. Rapid decrease
of tumor volume during the course of SBRT may be due to
apoptosis of the tumor cells [19]. In a study with murine
tumors, adenocarcinomas tended to show more apoptosis
after radiation than squamous cell carcinomas [20]. De-
crease of tumor volume during the SBRT course may not
pose a major problem, since this phenomenon only adds
margins of a few millimeters in the latter half of the course.
On the other hand, an increase of tumor volume can
adversely affect the dose distribution in PTV. According
to other investigators, a GTV increase of >10 cm3 was
observed during SBRT for NSCLC in two tumors in the
first 2 weeks of treatment [21]. In addition, 25% increase
of PTVs was observed on the repeat 4DCT scan [22].
In another study with 8 patients, slight increases anddecreases in GTV appeared to occur in a few patients
each, but overall GTV variations were not significant [23].
In all of these studies, the target volume was contoured
manually. Although the fractionation schedule and pre-
scribed dose are somewhat different, our study confirmed
that lung cancers could show temporary enlargement
in the first week during SBRT. We speculate that the
main reason for this phenomenon may be edema due to
high-dose irradiation, but sustained tumor progression
can be another cause in rapidly growing tumors.
What is the influence on the dose coverage for the
PTV? If sufficient margins are allowed at treatment
planning, such changes may not pose a serious problem
without making an adaptive treatment plan. In our SBRT
studies, the CTVs were somewhat larger than the esti-
mated tumor volumes, and we created the internal target
volume (ITV) using fusion images of three CT phases.
Furthermore, 5-mm margins were added to the ITV for
the PTV. With our present treatment protocol, therefore,
adaptive planning may not be necessary. Previous studies
addressed the issue of appropriate margin settings and
respiratory-gated irradiation using 4DCT [24-27]. These
studies indicated that the use of 4DCT could reduce the
PTV. In attempts at reducing the margin in the future, the
phenomenon of volume expansion during SBRT course
should be taken into account.
In summary, volume expansion over 10% was observed
in 32% of the tumors during the first week of SBRT. In
making SBRT plans, this phenomenon should be taken
into account.
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